SWOT Analysis – Jubilant Pharmova Limited

Strengths Diversified pharmaceutical platform across Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO and Generics. Strong presence in the US radiopharmaceutical market and a major US radiopharmacy network. FY26 revenue grew 14% YoY to ₹8,280 crore. CDMO Sterile Injectables revenue grew 38% YoY to ₹1,755 crore, supported by Spokane Line 3. Strong capabilities in drug discovery, APIs and complex sterile manufacturing. Ruby-Fill installations grew strongly during FY26. Weaknesses Complex multi-business structure creates execution and capital-allocation challenges. FY26 EBITDA margin was affected by lower SPECT production and the Montreal facility shutdown/remediation. Net debt/EBITDA stood at 1.3x in March 2026. Higher depreciation and interest costs can pressure net-profit growth. Some pharmaceutical businesses remain exposed to pricing pressure. Opportunities Strong growth potential in CDMO Sterile Injectables and complex pharmaceutical manufacturing. Spokane Line 3 has onboarded a major global oncology product. Multiple PET and SPECT imaging products are planned for future introduction. CRDMO expansion into biologics and antibody-drug conjugates through strategic partnerships. Growth in Ruby-Fill and international radiopharma penetration. Novel drug candidates JBI-802 and JBI-778 provide long-term pipeline optionality. Threats USFDA observations and manufacturing compliance risks. Regulatory delays in pharmaceutical product approvals. Pricing pressure in the API and generics markets. High competition from global CDMO and pharmaceutical companies. Facility shutdowns or production disruptions can materially affect margins. Clinical-trial failure and new-drug development risks.